Idioma:

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study

Torres, Tiago ; Chiricozzi, Andrea ; Puig, Luis ; Lé, Ana Maria ; Marzano, Angelo Valerio ; Dapavo, Paolo ; Dauden, Esteban ; Carrascosa, Jόse-Manuel ; Lazaridou, Elizabeth ; Duarte, Gleison ; Carvalho, André V. E. ; Romiti, Ricardo ; Rompoti, Natalia ; Teixeira, Laetitia ; Abreu, Miguel ; Ippoliti, Elena ; Maronese, Carlo Alberto ; Llamas-Velasco, Mar ; Vilarrasa, Eva ; del Alcázar, Elena ; Daponte, Athina-Ioanna ; Papoutsaki, Marina ; Carugno, Andrea ; Bellinato, Francesco ; Gisondi, Paolo

American journal of clinical dermatology, 2024-03, Vol.25 (2), p.333-342 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por

Enviar para

Título:
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study
Autor: Torres, Tiago ; Chiricozzi, Andrea ; Puig, Luis ; Lé, Ana Maria ; Marzano, Angelo Valerio ; Dapavo, Paolo ; Dauden, Esteban ; Carrascosa, Jόse-Manuel ; Lazaridou, Elizabeth ; Duarte, Gleison ; Carvalho, André V. E. ; Romiti, Ricardo ; Rompoti, Natalia ; Teixeira, Laetitia ; Abreu, Miguel ; Ippoliti, Elena ; Maronese, Carlo Alberto ; Llamas-Velasco, Mar ; Vilarrasa, Eva ; del Alcázar, Elena ; Daponte, Athina-Ioanna ; Papoutsaki, Marina ; Carugno, Andrea ; Bellinato, Francesco ; Gisondi, Paolo
Assuntos: Adult ; Dermatology ; Humans ; Interleukin Inhibitors ; Interleukin-17 ; Interleukin-23 - therapeutic use ; Latent Tuberculosis - diagnosis ; Latent Tuberculosis - epidemiology ; Latent Tuberculosis - prevention & control ; Medicine ; Medicine & Public Health ; Original ; Original Research Article ; Pharmacology/Toxicology ; Pharmacotherapy ; Psoriasis - complications ; Psoriasis - drug therapy ; Retrospective Studies ; Tuberculosis - complications
É parte de: American journal of clinical dermatology, 2024-03, Vol.25 (2), p.333-342
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Descrição: Background Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. Available evidence from clinical trials and real-world studies suggests that IL-17 and IL-23 inhibitors do not increase the risk of tuberculosis reactivation. Objective To evaluate psoriasis patients with treated or untreated newly diagnosed LTBI who received IL-17 and IL-23 inhibitors and the tolerability/safety of tuberculosis chemoprophylaxis. Methods This is a retrospective, observational, multinational study from a series of 14 dermatology centres based in Portugal, Spain, Italy, Greece and Brazil, which included adult patients with moderate-to-severe chronic plaque psoriasis and newly diagnosed LTBI who were treated with IL-23 or IL-17 inhibitors between January 2015 and March 2022. LTBI was diagnosed in the case of tuberculin skin test and/or interferon gamma release assay positivity, according to local guideline, prior to initiating IL-23 or IL-17 inhibitor. Patients with prior diagnosis of LTBI (treated or untreated) or treated active infection were excluded. Results A total of 405 patients were included; complete/incomplete/no chemoprophylaxis was administered in 62.2, 10.1 and 27.7% of patients, respectively. The main reason for not receiving or interrupting chemoprophylaxis was perceived heightened risk of liver toxicity and hepatotoxicity, respectively. The mean duration of biological treatment was 32.87 ± 20.95 months, and only one case of active tuberculosis infection (ATBI) was observed, after 14 months of treatment with ixekizumab. The proportion of ATBI associated with ixekizumab was 1.64% [95% confidence interval (CI): 0–5.43%] and 0% for all other agents and 0.46% (95% CI 0–1.06%) and 0% for IL-17 and IL-23 inhibitors, respectively (not statistically significant). Conclusions The risk of tuberculosis reactivation in patients with psoriasis and LTBI does not seem to increase with IL-17 or IL-23 inhibitors. IL-17 or IL-23 inhibitors should be preferred over TNF antagonists when concerns regarding tuberculosis reactivation exists. In patients with LTBI considered at high risk for developing complications related to chemoprophylaxis, this preventive strategy may be waived before initiating treatment with IL-17 inhibitors and especially IL-23 inhibitors.
Editor: Cham: Springer International Publishing
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study

Cham: Springer International Publishing

Buscando em bases de dados remotas. Favor aguardar.